BioVie Inc. Increase Decrease In Operating Lease Liability
BioVie Inc. (BIVI) reported Increase Decrease In Operating Lease Liability of -$74.46 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- BioVie Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$20.29K.
- BioVie Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$19.20K.
- BioVie Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$17.82K.
- BioVie Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$17.16K.
- BioVie Inc. increase decrease in operating lease liability for fiscal 2026 was -$74.46K.
- BioVie Inc. increase decrease in operating lease liability for fiscal 2025 was -$60.34K.
- BioVie Inc. increase decrease in operating lease liability for fiscal 2023 was -$38.88K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.29K derived: 10-K 12 month − S-1/A 9 month · filed 2026-08-13 | -$39.48K derived: sum of 2 quarters · filed 2026-08-13 | -$57.30K derived: sum of 3 quarters · filed 2026-08-13 | -$74.46K 10-K · filed 2026-08-13 |
| 2026-03-31 | -$19.20K derived: S-1/A 9 month − 10-Q 6 month · filed 2026-08-06 | -$37.01K derived: sum of 2 quarters · filed 2026-08-06 | -$54.18K S-1/A · filed 2026-08-06 | -$70.71K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$17.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-06 | -$34.98K 10-Q · filed 2026-02-06 | -$51.52K derived: sum of 3 quarters · filed 2026-08-13 | -$67.11K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | -$17.16K 10-Q · filed 2025-11-10 | -$33.70K derived: sum of 2 quarters · filed 2026-08-13 | -$49.30K derived: sum of 3 quarters · filed 2026-08-13 | -$63.66K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$16.54K derived: 10-K 12 month − S-1/A 9 month · filed 2026-08-13 | -$32.13K derived: sum of 2 quarters · filed 2026-08-13 | -$46.50K derived: sum of 3 quarters · filed 2026-08-13 | -$60.34K 10-K · filed 2026-08-13 |
| 2025-03-31 | -$15.60K derived: S-1/A 9 month − 10-Q 6 month · filed 2026-08-06 | -$29.96K derived: sum of 2 quarters · filed 2026-08-06 | -$43.81K S-1/A · filed 2026-08-06 | -$57.14K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$14.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-06 | -$28.21K 10-Q · filed 2026-02-06 | -$41.55K derived: sum of 3 quarters · filed 2026-08-06 | -$53.88K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-09-30 | -$13.84K 10-Q · filed 2025-11-10 | -$27.18K derived: sum of 2 quarters · filed 2026-08-06 | -$39.51K derived: sum of 3 quarters · filed 2026-08-06 | -$50.44K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-06-30 | -$13.34K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-06 | -$25.67K derived: sum of 2 quarters · filed 2026-08-06 | -$36.60K derived: sum of 3 quarters · filed 2026-08-06 | -$47.24K S-1/A · filed 2026-08-06 |
| 2024-03-31 | -$12.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | -$23.26K derived: sum of 2 quarters · filed 2025-05-12 | -$33.91K 10-Q · filed 2025-05-12 | -$44.27K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$10.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-11 | -$21.58K 10-Q · filed 2025-02-11 | -$31.94K derived: sum of 3 quarters · filed 2025-02-11 | -$41.79K derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-09-30 | -$10.64K 10-Q · filed 2024-11-13 | -$21.01K derived: sum of 2 quarters · filed 2024-11-13 | -$30.85K derived: sum of 3 quarters · filed 2024-11-13 | -$40.32K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$10.37K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | -$20.21K derived: sum of 2 quarters · filed 2024-09-30 | -$29.67K derived: sum of 3 quarters · filed 2024-09-30 | -$38.88K 10-K · filed 2024-09-30 |
| 2023-03-31 | -$9.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-14 | -$19.31K derived: sum of 2 quarters · filed 2024-05-14 | -$28.52K 10-Q · filed 2024-05-14 | |
| 2022-12-31 | -$9.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | -$18.68K 10-Q · filed 2024-02-13 | ||
| 2022-09-30 | -$9.21K 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |